22.28
price up icon8.05%   1.66
after-market 시간 외 거래: 22.28
loading
전일 마감가:
$20.62
열려 있는:
$21
하루 거래량:
691.04K
Relative Volume:
1.24
시가총액:
$1.34B
수익:
$1.23M
순이익/손실:
$-214.90M
주가수익비율:
-5.4049
EPS:
-4.1222
순현금흐름:
$-151.25M
1주 성능:
+7.12%
1개월 성능:
-6.62%
6개월 성능:
-24.47%
1년 성능:
-7.63%
1일 변동 폭
Value
$20.96
$22.82
1주일 범위
Value
$20.33
$22.82
52주 변동 폭
Value
$20.07
$47.97

Spyre Therapeutics Inc Stock (SYRE) Company Profile

Name
명칭
Spyre Therapeutics Inc
Name
전화
(617) 651-5940
Name
주소
221 CRESCENT STREET, WALTHAM
Name
직원
60
Name
트위터
Name
다음 수익 날짜
2024-11-07
Name
최신 SEC 제출 서류
Name
SYRE's Discussions on Twitter

SYRE을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
SYRE
Spyre Therapeutics Inc
22.28 1.34B 1.23M -214.90M -151.25M -4.1222
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
427.89 110.19B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
687.80 75.58B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
647.39 38.71B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
264.99 34.18B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
117.25 28.11B 3.30B -501.07M 1.03B -2.1146

Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-09-04 개시 Wedbush Outperform
2024-07-16 개시 Evercore ISI Outperform
2024-05-02 개시 Robert W. Baird Outperform
2024-03-01 업그레이드 Wells Fargo Equal Weight → Overweight
2023-12-20 개시 BTIG Research Buy
2023-12-11 개시 Guggenheim Buy
2023-12-11 개시 Jefferies Buy
2020-05-04 개시 Piper Sandler Overweight
2019-03-21 개시 JP Morgan Overweight
2018-09-04 다운그레이드 Wells Fargo Outperform → Market Perform
2018-04-24 개시 Evercore ISI Outperform
2018-03-14 재확인 Needham Buy
모두보기

Spyre Therapeutics Inc 주식(SYRE)의 최신 뉴스

pulisher
07:10 AM

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc.SYRE - PR Newswire

07:10 AM
pulisher
Jan 17, 2025

Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 5.3%What's Next? - MarketBeat

Jan 17, 2025
pulisher
Jan 17, 2025

Lifesci Capital Has Positive Outlook of SYRE FY2024 Earnings - Defense World

Jan 17, 2025
pulisher
Jan 16, 2025

FY2024 EPS Forecast for Spyre Therapeutics Lifted by Analyst - MarketBeat

Jan 16, 2025
pulisher
Jan 14, 2025

Spyre Therapeutics (NASDAQ:SYRE) Given Outperform Rating at Wedbush - Defense World

Jan 14, 2025
pulisher
Jan 13, 2025

Spyre Therapeutics (NASDAQ:SYRE) Given "Outperform" Rating at Wedbush - MarketBeat

Jan 13, 2025
pulisher
Jan 13, 2025

Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts - PR Newswire

Jan 13, 2025
pulisher
Jan 10, 2025

Spyre Therapeutics (NASDAQ:SYRE) Trading Down 9.2%Here's Why - MarketBeat

Jan 10, 2025
pulisher
Jan 07, 2025

Spyre Therapeutics (NASDAQ:SYRE) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat

Jan 07, 2025
pulisher
Jan 05, 2025

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by Jane Street Group LLC - Defense World

Jan 05, 2025
pulisher
Jan 03, 2025

Spyre Therapeutics Awards Key Employee Stock Options at $24.35 with 10-Year Term - StockTitan

Jan 03, 2025
pulisher
Jan 02, 2025

Spyre Therapeutics Announces Grants of Inducement Awards - PR Newswire

Jan 02, 2025
pulisher
Jan 01, 2025

Brokerages Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) Price Target at $51.50 - Defense World

Jan 01, 2025
pulisher
Dec 29, 2024

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat

Dec 29, 2024
pulisher
Dec 27, 2024

Geode Capital Management LLC Has $26.21 Million Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Dec 27, 2024
pulisher
Dec 27, 2024

Geode Capital Management LLC Purchases 125,214 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat

Dec 27, 2024
pulisher
Dec 25, 2024

Contrasting Spyre Therapeutics (NASDAQ:SYRE) & Generation Bio (NASDAQ:GBIO) - Defense World

Dec 25, 2024
pulisher
Dec 24, 2024

Spyre Therapeutics (NASDAQ:SYRE) Shares Down 2.5%Here's Why - MarketBeat

Dec 24, 2024
pulisher
Dec 24, 2024

Barclays PLC Buys 41,424 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Dec 24, 2024
pulisher
Dec 24, 2024

Barclays PLC Boosts Stock Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat

Dec 24, 2024
pulisher
Dec 23, 2024

Spyre Therapeutics is Now Oversold (SYRE) - Nasdaq

Dec 23, 2024
pulisher
Dec 20, 2024

State Street Corp Buys 131,896 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat

Dec 20, 2024
pulisher
Dec 20, 2024

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 3,680 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Dec 20, 2024
pulisher
Dec 18, 2024

Spyre Therapeutics Added to the Nasdaq Biotechnology Index - PR Newswire

Dec 18, 2024
pulisher
Dec 17, 2024

Evercore ISI Group Initiates Coverage of Spyre Therapeutics (SYRE) with Outperform Recommendation - MSN

Dec 17, 2024
pulisher
Dec 16, 2024

Jones Trading Initiates Coverage of Spyre Therapeutics (SYRE) with Hold Recommendation - MSN

Dec 16, 2024
pulisher
Dec 12, 2024

The Manufacturers Life Insurance Company Has $1.28 Million Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Dec 12, 2024
pulisher
Dec 12, 2024

Spyre Therapeutics: Different Name, Same Tune (NASDAQ:SYRE) - Seeking Alpha

Dec 12, 2024
pulisher
Dec 12, 2024

Wellington Management Group LLP Has $44.33 Million Stock Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat

Dec 12, 2024
pulisher
Dec 10, 2024

Charles Schwab Investment Management Inc. Has $9.80 Million Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat

Dec 10, 2024
pulisher
Dec 07, 2024

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Bought by Janus Henderson Group PLC - MarketBeat

Dec 07, 2024
pulisher
Dec 04, 2024

61,256 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Purchased by Cinctive Capital Management LP - MarketBeat

Dec 04, 2024
pulisher
Dec 04, 2024

Analysts Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) PT at $48.57 - MarketBeat

Dec 04, 2024
pulisher
Dec 03, 2024

SPYRE ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire

Dec 03, 2024
pulisher
Dec 03, 2024

Spyre Therapeutics begins dosing subjects in Phase I trials of anti-TL1A antibodies - Yahoo Finance

Dec 03, 2024
pulisher
Dec 03, 2024

Spyre begins Phase 1 trials for new IBD treatments By Investing.com - Investing.com Canada

Dec 03, 2024
pulisher
Dec 03, 2024

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Bought by Fmr LLC - MarketBeat

Dec 03, 2024
pulisher
Dec 02, 2024

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies - PR Newswire

Dec 02, 2024
pulisher
Dec 02, 2024

Spyre Therapeutics Launches Phase 1 Trials for Revolutionary Long-Acting IBD Treatment - StockTitan

Dec 02, 2024
pulisher
Dec 01, 2024

Walleye Capital LLC Increases Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat

Dec 01, 2024
pulisher
Nov 30, 2024

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Sold by Braidwell LP - MarketBeat

Nov 30, 2024
pulisher
Nov 29, 2024

Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Stockholders to Inquire about Securities Investigation - AccessWire

Nov 29, 2024
pulisher
Nov 28, 2024

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Investors to Learn More About the Investigation - AccessWire

Nov 28, 2024
pulisher
Nov 28, 2024

SYRESpyre Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Nov 28, 2024
pulisher
Nov 27, 2024

Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire

Nov 27, 2024
pulisher
Nov 26, 2024

Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Connect - AccessWire

Nov 26, 2024
pulisher
Nov 26, 2024

Spyre Therapeutics’ $200 Million Common Stock Offering - Global Legal Chronicle

Nov 26, 2024
pulisher
Nov 25, 2024

Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference - PR Newswire

Nov 25, 2024

Spyre Therapeutics Inc (SYRE) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$21.80
price up icon 4.81%
$73.47
price up icon 2.14%
$22.10
price up icon 16.13%
$367.97
price up icon 2.52%
biotechnology ONC
$218.70
price up icon 4.10%
$117.25
price up icon 4.75%
자본화:     |  볼륨(24시간):